SCHEMBL24005288

SCHEMBL24005288

CCOC(=O)CNC(=O)c1c(O)[nH]c(=O)[nH]c1=O

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.55
MAPT P10636 2/20 0.55
KDM4E B2RXH2 2/20 0.55
KMT2A Q03164 2/20 0.55
HPGD P15428 2/20 0.55
MEN1 O00255 1/20 0.55
USP2 O75604 1/20 0.55
LMNA P02545 1/20 0.55
POLB P06746 1/20 0.55
CASP1 P29466 1/20 0.55
BRCA1 P38398 1/20 0.55
HTT P42858 1/20 0.55
CASP7 P55210 1/20 0.55
HSD17B10 Q99714 1/20 0.55
TDP1 Q9NUW8 1/20 0.55
L3MBTL1 Q9Y468 1/20 0.55
SMN1; SMN2 Q16637 3/20 0.46
XDH P47989 7/20 0.43
SLC22A12 Q96S37 5/20 0.43
NPC1 O15118 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3421207 0.79 SLC22A12 (0.54) ALDH1A1MAPTKDM4EKMT2AHPGD
SCHEMBL4997699 0.71 HSD17B10 (0.58) ALDH1A1KDM4EHPGDUSP2LMNA
SCHEMBL3422087 0.70 ALDH1A1 (0.61) ALDH1A1KDM4EKMT2AHPGDMEN1
SCHEMBL3420468 0.70 HPGD (0.49) ALDH1A1KDM4EKMT2AHPGDMEN1
SCHEMBL20929164 0.66 SMN1; SMN2 (0.51) ALDH1A1MAPTKDM4EKMT2AHPGD
SCHEMBL13528588 0.66 SMN1; SMN2 (0.53) ALDH1A1MAPTKDM4EHPGDLMNA
SCHEMBL18754170 0.66 HTT (0.60) ALDH1A1MAPTHPGDCASP1HTT
SCHEMBL8545504 0.65 HPGD (0.56) ALDH1A1MAPTKDM4EKMT2AHPGD
SCHEMBL833589 0.65 NPC1 (0.68) ALDH1A1MAPTKDM4EKMT2AMEN1
SCHEMBL19107122 0.65 XDH (0.72) ALDH1A1MAPTKDM4EKMT2AHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230227414-A1 Prolyl Hydroxylase Inhibitors GLAXOSMITHKLINE LLC (US) 2023-07-20 US disclosed
US-11643397-B2 Prolyl hydroxylase inhibitors GLAXOSMITHKLINE LLC (US) 2023-05-09 US disclosed
US-20210347740-A1 Prolyl Hydroxylase Inhibitors GLAXOSMITHKLINE LLC (US) 2021-11-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11643397-B2 Prolyl hydroxylase inhibitors HIF1AN, EGLN3, EGLN2 ALDH1A1 242/4885MAPT 4599/4885KDM4E 625/4885
US-20210347740-A1 Prolyl Hydroxylase Inhibitors HIF1AN, EGLN3, EGLN2 ALDH1A1 242/4885MAPT 4599/4885KDM4E 625/4885
US-20230227414-A1 Prolyl Hydroxylase Inhibitors HIF1AN, EGLN3, EGLN2 ALDH1A1 242/4885MAPT 4599/4885KDM4E 625/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.